SG11201701630VA - Treatment of androgen deprivation therapy associated symptoms - Google Patents
Treatment of androgen deprivation therapy associated symptomsInfo
- Publication number
- SG11201701630VA SG11201701630VA SG11201701630VA SG11201701630VA SG11201701630VA SG 11201701630V A SG11201701630V A SG 11201701630VA SG 11201701630V A SG11201701630V A SG 11201701630VA SG 11201701630V A SG11201701630V A SG 11201701630VA SG 11201701630V A SG11201701630V A SG 11201701630VA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- associated symptoms
- androgen deprivation
- deprivation therapy
- therapy associated
- Prior art date
Links
- 238000009167 androgen deprivation therapy Methods 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Neurology (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049192P | 2014-09-11 | 2014-09-11 | |
| PCT/US2015/048801 WO2016040234A1 (en) | 2014-09-11 | 2015-09-08 | Treatment of androgen deprivation therapy associated symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701630VA true SG11201701630VA (en) | 2017-03-30 |
Family
ID=54151401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701630VA SG11201701630VA (en) | 2014-09-11 | 2015-09-08 | Treatment of androgen deprivation therapy associated symptoms |
| SG10201809673RA SG10201809673RA (en) | 2014-09-11 | 2015-09-08 | Treatment of androgen deprivation therapy associated symptoms |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201809673RA SG10201809673RA (en) | 2014-09-11 | 2015-09-08 | Treatment of androgen deprivation therapy associated symptoms |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US10758515B2 (enExample) |
| EP (2) | EP3191094B1 (enExample) |
| JP (4) | JP6893171B2 (enExample) |
| KR (5) | KR20210083370A (enExample) |
| CN (4) | CN113521068A (enExample) |
| AP (1) | AP2017009795A0 (enExample) |
| AU (2) | AU2015315431C1 (enExample) |
| BR (2) | BR112017002449B1 (enExample) |
| CA (2) | CA2956514C (enExample) |
| EA (2) | EA034553B1 (enExample) |
| ES (1) | ES2779978T3 (enExample) |
| HK (1) | HK1252811A1 (enExample) |
| IL (3) | IL279209B2 (enExample) |
| JO (2) | JOP20180072A1 (enExample) |
| MA (1) | MA45416A (enExample) |
| MX (3) | MX373322B (enExample) |
| MY (2) | MY195767A (enExample) |
| NZ (1) | NZ728612A (enExample) |
| SG (2) | SG11201701630VA (enExample) |
| TW (1) | TWI616201B (enExample) |
| UA (1) | UA120099C2 (enExample) |
| WO (1) | WO2016040234A1 (enExample) |
| ZA (1) | ZA201802680B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20180072A1 (ar) * | 2014-09-11 | 2019-01-30 | Lilly Co Eli | علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين |
| US20180185347A1 (en) * | 2016-11-16 | 2018-07-05 | Transition Therapeutics (Ireland 2) Limited | Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp |
| US20230096602A1 (en) | 2020-01-27 | 2023-03-30 | Eirgen Pharma Ltd. | Tetrahydrocyclopenta[b]indole compounds for treatment of renal disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007536A (es) * | 2003-01-13 | 2005-10-20 | Gtx Inc | Sintesis a gran escala de moduladores de receptor de androgeno selectivos. |
| US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
| US9889110B2 (en) * | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
| JP2009538873A (ja) | 2006-05-31 | 2009-11-12 | グラクソ グループ リミテッド | 新規複素環化合物 |
| MX2009000714A (es) * | 2006-07-19 | 2009-07-27 | Osurf | Moduladores de receptor de androgeno selectivos, analogos y derivados de los mismos. |
| US7443672B2 (en) | 2006-10-03 | 2008-10-28 | Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. | Video graphics array (VGA) card assembly |
| UA98777C2 (en) * | 2006-11-20 | 2012-06-25 | Эли Лилли Энд Компани | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
| TW200918521A (en) * | 2007-08-31 | 2009-05-01 | Astrazeneca Ab | Heterocyclic amides and methods of use thereof |
| US8420624B2 (en) | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
| MX2010006972A (es) * | 2007-12-21 | 2010-08-26 | Ligand Pharm Inc | Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos. |
| BRPI0912394A2 (pt) * | 2008-05-16 | 2016-07-26 | Lilly Co Eli | moduladores do receptor de androgênio à base de tetra-hidrociclopenta[b]indol |
| US8003689B2 (en) * | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| AR078862A1 (es) * | 2009-11-13 | 2011-12-07 | Lilly Co Eli | Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia |
| CN102234287B (zh) * | 2010-04-26 | 2015-08-05 | 上海阳帆医药科技有限公司 | 硝基咪唑类化合物、其制备方法和用途 |
| JP2012149054A (ja) * | 2010-12-27 | 2012-08-09 | Dainippon Sumitomo Pharma Co Ltd | Ｎ−置換−環状アミノ誘導体からなる医薬 |
| LT2915804T (lt) * | 2012-10-31 | 2019-06-10 | Fujifilm Toyama Chemical Co., Ltd. | Nauji amino dariniai arba jo druskos kaip tnf alfa inhibitoriai |
| JP6469692B2 (ja) * | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| JOP20180072A1 (ar) * | 2014-09-11 | 2019-01-30 | Lilly Co Eli | علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين |
-
2014
- 2014-09-11 JO JOP/2018/0072A patent/JOP20180072A1/ar unknown
-
2015
- 2015-08-25 TW TW104127732A patent/TWI616201B/zh active
- 2015-08-25 JO JOP/2015/0201A patent/JO3609B1/ar active
- 2015-09-08 KR KR1020217019807A patent/KR20210083370A/ko not_active Ceased
- 2015-09-08 KR KR1020187010670A patent/KR102024493B1/ko active Active
- 2015-09-08 CN CN202110830219.4A patent/CN113521068A/zh active Pending
- 2015-09-08 AP AP2017009795A patent/AP2017009795A0/en unknown
- 2015-09-08 EP EP15767383.1A patent/EP3191094B1/en active Active
- 2015-09-08 CN CN201580048887.4A patent/CN106794178A/zh active Pending
- 2015-09-08 MX MX2017003140A patent/MX373322B/es active IP Right Grant
- 2015-09-08 KR KR1020177006425A patent/KR20170040338A/ko not_active Ceased
- 2015-09-08 US US15/327,054 patent/US10758515B2/en active Active
- 2015-09-08 WO PCT/US2015/048801 patent/WO2016040234A1/en not_active Ceased
- 2015-09-08 KR KR1020197003498A patent/KR20190015628A/ko not_active Ceased
- 2015-09-08 JP JP2017513539A patent/JP6893171B2/ja active Active
- 2015-09-08 ES ES15767383T patent/ES2779978T3/es active Active
- 2015-09-08 CA CA2956514A patent/CA2956514C/en active Active
- 2015-09-08 CN CN201810348598.1A patent/CN108440497A/zh active Pending
- 2015-09-08 CN CN202110871107.3A patent/CN113651797A/zh active Pending
- 2015-09-08 EP EP18169909.1A patent/EP3375444A1/en not_active Withdrawn
- 2015-09-08 IL IL279209A patent/IL279209B2/en unknown
- 2015-09-08 MY MYPI2018000825A patent/MY195767A/en unknown
- 2015-09-08 NZ NZ728612A patent/NZ728612A/en not_active IP Right Cessation
- 2015-09-08 BR BR112017002449-7A patent/BR112017002449B1/pt active IP Right Grant
- 2015-09-08 SG SG11201701630VA patent/SG11201701630VA/en unknown
- 2015-09-08 KR KR1020227032523A patent/KR102619415B1/ko active Active
- 2015-09-08 SG SG10201809673RA patent/SG10201809673RA/en unknown
- 2015-09-08 MA MA045416A patent/MA45416A/fr unknown
- 2015-09-08 MX MX2018004731A patent/MX391447B/es unknown
- 2015-09-08 BR BR122018007412-4A patent/BR122018007412B1/pt active IP Right Grant
- 2015-09-08 EA EA201891008A patent/EA034553B1/ru active IP Right Revival
- 2015-09-08 UA UAA201701774A patent/UA120099C2/uk unknown
- 2015-09-08 AU AU2015315431A patent/AU2015315431C1/en active Active
- 2015-09-08 MY MYPI2017700838A patent/MY198753A/en unknown
- 2015-09-08 EA EA201790220A patent/EA033606B1/ru not_active IP Right Cessation
- 2015-09-08 CA CA3067289A patent/CA3067289C/en active Active
-
2017
- 2017-01-25 IL IL250291A patent/IL250291B/en active IP Right Grant
- 2017-03-09 MX MX2021014120A patent/MX2021014120A/es unknown
- 2017-07-20 HK HK18112116.4A patent/HK1252811A1/en unknown
-
2018
- 2018-04-11 IL IL258651A patent/IL258651B/en active IP Right Grant
- 2018-04-18 AU AU2018202714A patent/AU2018202714B2/en active Active
- 2018-04-23 ZA ZA2018/02680A patent/ZA201802680B/en unknown
- 2018-12-11 US US16/216,256 patent/US10799478B2/en active Active
-
2019
- 2019-01-23 JP JP2019009535A patent/JP6938550B2/ja active Active
-
2020
- 2020-08-26 US US17/003,648 patent/US20200390744A1/en not_active Abandoned
-
2021
- 2021-09-01 JP JP2021142082A patent/JP7349480B2/ja active Active
-
2023
- 2023-07-06 JP JP2023111531A patent/JP2023145479A/ja active Pending
- 2023-12-12 US US18/537,308 patent/US20240148694A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252839A0 (en) | Treatment of boils | |
| IL250960A0 (en) | Combined treatment of sinecriviroc for the treatment of leprosy | |
| PL3851537T3 (pl) | Leczenie hiperbilirubinemii | |
| GB201701673D0 (en) | Methods of well treatment | |
| PT3212233T (pt) | Terapia combinada para o tratamento de doenças | |
| IL250677A0 (en) | Cancer treatment using anti-nkg2a agents | |
| IL285003A (en) | Treatment of episode disorders | |
| GB201410116D0 (en) | Method of treatment | |
| SG11201609993YA (en) | Treatment of immune disorders | |
| IL246880A0 (en) | Tumor treatment | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201408387D0 (en) | Treatment of respiratory disorders | |
| IL279209A (en) | Treatment of symptoms associated with androgen deprivation therapies | |
| GB201408297D0 (en) | Treatment of cancer | |
| IL251350A0 (en) | Treatment of Rett syndrome | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| GB201417248D0 (en) | Compostion and methods of treatment | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201417456D0 (en) | Treatment of cancer | |
| GB201407806D0 (en) | Treatment of fibrosis | |
| PT3851537T (pt) | Tratamento da hiperbilirrubinemia | |
| SG10201913141UA (en) | Treatment of alphavirus-induced inflammation | |
| GB201417465D0 (en) | Treatment of cancers | |
| GB201409362D0 (en) | Treatment of cancer | |
| GB201405449D0 (en) | Treatment of cancer |